Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurochem ; 109(5): 1225-36, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19476541

ABSTRACT

Cytosolic Ca(2+) concentration ([Ca(2+)](i)) is reduced in cultured neurons undergoing neuronal death caused by inhibitors of the ubiquitin proteasome system. Activation of calcium entry via voltage-gated Ca(2+) channels restores cytosolic Ca(2+) levels and reduces this neuronal death (Snider et al. 2002). We now show that this reduction in [Ca(2+)](i) is transient and occurs early in the cell death process, before activation of caspase 3. Agents that increase Ca(2+) influx such as activation of voltage-gated Ca(2+) channels or stimulation of Ca(2+) entry via the plasma membrane Na-Ca exchanger attenuate neuronal death only if applied early in the cell death process. Cultures treated with proteasome inhibitors had reduced current density for voltage-gated Ca(2+) channels and a less robust increase in [Ca(2+)](i) after depolarization. Levels of endoplasmic reticulum Ca(2+) were reduced and capacitative Ca(2+) entry was impaired early in the cell death process. Mitochondrial Ca(2+) was slightly increased. Preventing the transfer of Ca(2+) from mitochondria to cytosol increased neuronal vulnerability to this death while blockade of mitochondrial Ca(2+) uptake via the uniporter had no effect. Programmed cell death induced by proteasome inhibition may be caused in part by an early reduction in cytosolic and endoplasmic reticulum Ca(2+,) possibly mediated by dysfunction of voltage-gated Ca(2+) channels. These findings may have implications for the treatment of disorders associated with protein misfolding in which proteasome impairment and programmed cell death may occur.


Subject(s)
Calcium/deficiency , Cysteine Proteinase Inhibitors/pharmacology , Leupeptins/pharmacology , Neurons/drug effects , Proteasome Inhibitors , 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester/pharmacology , Amiloride/analogs & derivatives , Amiloride/pharmacology , Animals , Astrocytes/drug effects , Biophysics , Calcium Channel Blockers/pharmacology , Cell Death/drug effects , Cells, Cultured , Cytosol/drug effects , Cytosol/metabolism , Cytosol/ultrastructure , Dose-Response Relationship, Drug , Electric Stimulation/methods , Embryo, Mammalian , Endoplasmic Reticulum/drug effects , Endoplasmic Reticulum/metabolism , Excitatory Amino Acid Agonists/pharmacology , Lactones/pharmacology , Membrane Potentials/drug effects , Membrane Potentials/physiology , Mice , Neocortex/cytology , Neurons/cytology , Patch-Clamp Techniques/methods , Sesquiterpenes/pharmacology , Time Factors
2.
J Neurochem ; 91(4): 996-1006, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15525353

ABSTRACT

We report here that exposure to low concentrations of proteasome inhibitors (e.g. 10-100 nm MG-132, 0.1-3 nm epoxomicin or 10-30 nm clasto-lactacystin beta-lactone) resulted in an enhancement, rather than an inhibition, of proteasome activity in cultured neocortical neurons. Size-fractionation chromatography confirmed that the enhanced peptide cleavage activity was associated with proteasome-sized complexes. This sub toxic exposure reduced neuronal death caused by subsequent exposure to oxidative stress (100-200 microm H(2)O(2) for 30 min, 24-h exposure to 100 microm paraquat or 7.5 microm menadione), but did not alter vulnerability to excitotoxicity (5-min exposure to 30-100 microm NMDA or 24 exposure to 12 microm NMDA). Sub toxic proteasome inhibitor exposure caused an increase in levels of proteasome core subunit proteins and mRNAs, but not in levels of potentially cytoprotective heat shock proteins (hsp70, hsp90 and hsp40). The neuroprotective effects of proteasome inhibitor pre-treatment were blocked by coapplication of proteasome inhibitors during the oxidative insult. These findings support a model in which sublethal proteasome inhibition induces neurons to increase proteasome activity and promotes resistance to oxidative injury and suggests that enhancement of proteasome activity is a potential therapeutic target for diseases in which oxidative stress has been implicated.


Subject(s)
Enzyme Inhibitors/pharmacology , Neurons/drug effects , Neurons/enzymology , Oxidative Stress/drug effects , Proteasome Endopeptidase Complex/drug effects , Proteasome Endopeptidase Complex/metabolism , Animals , Cell Death/drug effects , Cells, Cultured , Cytoprotection/drug effects , Dose-Response Relationship, Drug , Enzyme Activation/drug effects , Mice , Neuroprotective Agents/pharmacology , Oxidants/toxicity , Oxidative Stress/physiology , Proteasome Endopeptidase Complex/genetics , RNA, Messenger/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...